Bitcoin sets a new all-time high above $6,000 >>> READ MORE

Bull’s Eye Report: United Therapeutics Group (UTHR)

UTHR is cream of the crop in the biotech space


At, we strive to “own the best and ignore the rest” in our equity portfolios. Toward this end, each day we search our database for a “top stock” (a top rated company in terms of earnings strength as well as company and industry performance) that presents a strong technical “set up” and a good entry point.

In short, when our equity team is looking to add a stock to one of our portfolios, the “bull’s eye” stock shown below is generally their first choice.

Company Symbol Industry Stock Rating YTD% Gain S.T.
Stop Loss
United Therapeutics Corp. UTHR Biotechnology 9.8 +11.95% $59.02

Why We Like The Stock:

United Therapeutics Corp. (NASDAQ:UTHR) is our most compelling buy today due to the fact that it is a top rated stock (in terms of earnings strength and company/industry performance) in the top rated industry, biotechnology. Biotech stocks have been absolutely on fire this month, and the sub-industry is rated the highest in our momentum rankings. While the Health Care SPDR ETF (NYSE:XLV) is outperforming, it only takes a quick glance at the SPDR Biotechnology ETF (NYSE:XBI) to see where the upward thrust is coming from. UTHR has been having a great year so far, and has been trending higher since late October 2012. The last time the stock closed below its 50-day moving average was in early December, which is a great sign. In early April and again last week, UTHR held support around $59.50, and looks like it has turned a corner. Currently, the stock is crossing above its short-term moving averages and looks poised for a run back up to recent mid-March highs just north of $63. We like this reasonably priced biotech company here as long as it holds above its April 5 low of $59.02.

We Would Be Buyers:

At the current price (~$61.00), or on a pullback to the 50-day moving average ($59.69).

Company Profile:

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents and Cell-Based Therapy. Its product portfolio includes Remodulin, Tyvaso, Adcirca, Oral Treprostinil (UT-15C), Oral Treprostinil (UT-15C) Combination Therapy, Ch14.18 MAb, Beraprost-MR, 8H9 MAb, IW001, Glycobiology Antiviral Agents, PLX Cells, and Pulmonary Tissue Replacement and Remodeling. On July 11, 2011, the company acquired 100% interest in Revivicor, Inc. (Revivicor). On March 31, 2011, the Company sold 100% interest in Medicomp, Inc. (Medicomp). In June 2011, it discontinued its telemedicine-related activities.

Stock Rating: 9.8

The Stock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 – 10 with 10 being the highest.

United Therapeutics Group – Last Three Months


United Therapeutics Group – Last 12 Months


United Therapeutics Group – Last Five Years

Looking to trade the Bull’s Eye stock picks? Click here to download our free Special Report, “How We Identify Our “Bull’s Eye” Picks & How You Can Profit Trading Them”
At the time of publication the editor and affiliated companies own the following positions: UTHR

Note: Positions may be bought or sold while this publication is in circulation without notice.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC